3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
44
Paclitaxel
37
Carboplatin
30
Doxorubicin
11
Cisplatin
11
Bevacizumab
11
lenvatinib
9
Nivolumab
9
Docetaxel
9
Fulvestrant
8
Gemcitabine
7
Oxaliplatin
6
Fluorouracil
6
Pemetrexed
5
Letrozole
5
Ipilimumab
5
Cetuximab
5
spartalizumab
4
selinexor
4
dostarlimab
4
Trastuzumab
4
Irinotecan
4
trastuzumab deruxtecan
3
tisotumab vedotin
3
serabelisib
3
sacituzumab govitecan
3
ribociclib
3
olaparib
3
epacadostat
3
durvalumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Endometrial Neoplasms
×
Biopsy, Large-Core Needle
×
Clear all
NCT05520099
2026-04-29
ELEPHAS-02
Elephas
Active not recruiting
416 enrolled